STOCKWATCH
·
Pharmaceuticals
Quarterly Result14 May 2025, 04:33 pm

Hikal Ltd. Achieves Revenue of Rs 1860 Cr in FY25 with Improved EBITDA Margin and Strong Cashflow

AI Summary

Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its audited financial results for the quarter and full year ended 31st March 2025. The company reported a revenue of Rs 1860 Cr for the financial year and an EBITDA of Rs 328 Cr with a margin of 17.7%. The results reflect a clear alignment to positive global trends, particularly the shift toward innovation-driven outsourcing, regulatory compliance, and demand for sustainable, niche solutions. The company's balance sheet has further strengthened with an improved Net Debt/Equity ratio and better cash flow from operations.

Key Highlights

  • Revenue of Rs 1860 Cr and EBITDA of Rs 328 Cr in FY25
  • Improvement in EBITDA margin to 17.7%
  • Strengthened balance sheet with improved operating cashflow and reduction in debt
  • Positive financial performance in FY25
  • Recommended final dividend of 40% of FV
HIKAL
Pharmaceuticals
HIKAL LTD.

Price Impact